Matches in Nanopublications for { ?s ?p "[In addition, collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- assertion description "[In addition, collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In addition, collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1083147.RAZYllq5TJoLiVJMG8oQeVU5LO46yoJ6RUvWHMslEapWg130_assertion description "[In addition, collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1083147.RAZYllq5TJoLiVJMG8oQeVU5LO46yoJ6RUvWHMslEapWg130_provenance.
- NP747523.RABC06EukadKnb-vjZa6JMhtzDd0YSfsKYAJVX1CcFB-c130_assertion description "[In addition, collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP747523.RABC06EukadKnb-vjZa6JMhtzDd0YSfsKYAJVX1CcFB-c130_provenance.
- NP747527.RAryYzBS3Fg53wgJ2kCHHoQhPHzI4svC1rgZ2bm171NXc130_assertion description "[In addition, collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP747527.RAryYzBS3Fg53wgJ2kCHHoQhPHzI4svC1rgZ2bm171NXc130_provenance.
- NP1083143.RALRNmBGHzPNwVo6QB9XHtBXV_dI9Y4JBNfFaY6OoRaNM130_assertion description "[In addition, collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1083143.RALRNmBGHzPNwVo6QB9XHtBXV_dI9Y4JBNfFaY6OoRaNM130_provenance.
- NP747529.RAIOPx9X_auzz4k6PZ6hzrfVrNkiji-tqD-bEFrJ7xSFU130_assertion description "[In addition, collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP747529.RAIOPx9X_auzz4k6PZ6hzrfVrNkiji-tqD-bEFrJ7xSFU130_provenance.
- NP1083146.RA0IjXLhz8g1i8E1iwX35gMgmVBaGzUuwEdnLsSGN9duM130_assertion description "[In addition, collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1083146.RA0IjXLhz8g1i8E1iwX35gMgmVBaGzUuwEdnLsSGN9duM130_provenance.